ClinicaliQ Trial Snapshot
- A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer — Recruiting • Phase III • Oncology • NCT06072781.
- Treatment being tested: A combination of two targeted therapies—avutometinib (a MEK inhibitor) and defactinib (a FAK inhibitor)—compared against standard investigator-selected treatments in patients with recurrent low-grade serous ovarian cancer (LGSOC) that has progressed after platinum-based chemotherapy.
- Patient eligibility overview: The trial recruits patients with histologically confirmed recurrent LGSOC who have experienced disease progression following at least one prior platinum-based chemotherapy regimen, representing a treatment-resistant population with limited standard options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Eligibility Snapshot
- : Patients may be eligible for inclusion in the study if they meet the following criteria: 1. Histologically proven LGSOC (ovarian, fallopian, peritoneal) 2. Documented mutational status of KRAS by a validated tumor-tissue based diagnostic test. 3. Suitable for treatment with at least one of the Investigator's Choice of Treatments:pegylated liposomal doxorubicin, paclitaxel, letrozole, anastrozole. 4. Progression or recurrence of LGSOC after at least one prior systemic therapy for metastatic disease. 5. Measurable disease according to RECIST v1.1. 6. An Eastern Cooperative Group (ECOG) performance status ≤ 1. 7. Adequate organ function. 8. Adequate recovery from toxicities related to prior treatments. 9. For patients with reproductive potential, a negative pregnancy test must be confirmed and agreement to use highly effective method of contraceptive. 10. Willingness to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.